Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03154320
Other study ID # AI131998
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 6, 2017
Est. completion date April 16, 2021

Study information

Verified date September 2022
Source Brigham and Women's Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, unblinded study comparing standard vs. same-day treatment for patients with TB symptoms (cough, fever, night sweats, or weight loss) at HIV diagnosis. Six hundred patients will be randomized in a 1:1 ratio to the standard group or the same-day treatment group. All study activities will take place at the GHESKIO Centers in Port-au-Prince, Haiti. The study population includes HIV-infected men and women ≥18 years of age who are ART-naïve, and who present with symptoms of TB (cough, fever, nights sweats, or weight loss) at HIV diagnosis.


Description:

This study is a randomized trial that will compare outcomes with standard and same-day treatment among patients with TB symptoms at HIV diagnosis. The standard group will receive same-day chest x-ray as well as Xpert Ultra testing with a spot specimen (with 48-hour turn-around-time). Participants will return for Xpert Ultra results and early morning sputum testing on Day 2. TB treatment will be provided on the day of diagnosis (Day 0 for those with high clinical and radiographic suspicion of TB, and Day 2 for those diagnosed by spot Xpert Ultra). Standard group participants who are not diagnosed with TB will be tested and treated for other opportunistic infections (OIs), as clinically indicated, and will initiate ART on Day 7. The same-day group will receive Xpert Ultra testing (with same-day results) and chest x-ray with same-day ART or TB treatment (on Day 0) based on test results. They will also be tested and treated for other OIs as clinically indicated. They will provide early morning sputum for repeat testing on Day 1. Both groups will receive Xpert Ultra testing on both spot and early morning specimens, with liquid culture on both specimens as the diagnostic gold standard; those with TB will start ART according to WHO guidelines. Three specific aims are proposed: Aim 1: To compare the proportion of participants in each group who are alive and in care with undetectable viral load (<200 copies/ml) at 48 weeks after HIV testing. Hypothesis: The proportion of participants retained in care with undetectable viral load will be 51% in the standard and 65% in the same-day group. Aim 2: To compare mortality in each group at 48 weeks after HIV testing. Hypothesis: Mortality will be 10% in the standard group and 4% in the same-day group. Aim 3: To conduct a comparison of cost and cost-effectiveness of standard and same-day care, where cost is measured by the mean treatment cost and effectiveness is measured by being alive and in care with plasma HIV-1 RNA level <200 copies/ml at 48 weeks after HIV testing. Hypothesis: Same-day treatment will cost less per patient retained in care with undetectable viral load. Aim 4: To determine the rates of ART and TB treatment initiation, TB diagnosis after ART initiation, IRIS, adverse events, and adherence in both groups, and to evaluate the sensitivity, specificity, and predictive values of single tests and different testing combinations compared to liquid mycobacterial culture results.


Recruitment information / eligibility

Status Completed
Enrollment 500
Est. completion date April 16, 2021
Est. primary completion date April 16, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Men and women of =18 years of age - Presence of cough, fever, night sweats or weight loss - Ability and willingness to give written informed consent - Documentation of positive HIV status (test conducted at GHESKIO) - Acceptance of HIV diagnosis, defined as affirmative responses to two questions: "I believe that HIV and AIDS exist" and "I believe that the results of my HIV test show that I am infected". Exclusion Criteria: - Any use of ART in the past - Treatment for TB in the year prior to screening visit - Pregnancy or breastfeeding at the screening visit - Active drug, alcohol use, or mental condition that would interfere with the ability to adhere to study requirements, in the opinion of the study physician - Score of <3 for any of the 7 questions on the ART readiness survey - Planning to transfer care to another clinic during the study period - Symptoms consistent with WHO stage 4 neurologic disease (cryptococcal meningitis, TB meningitis; central nervous system toxoplasmosis; HIV encephalopathy; progressive multifocal leukoencephalopathy) - Severe illness, classified as one of the WHO "danger signs" of temperature >39 degrees Celsius, pulse >120 beats/minutes, respiratory rate >30, or inability to walk unaided.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Same-Day Treatment
Treatment with ART or TB medication on day of HIV diagnosis
Standard treatment
Standard treatment

Locations

Country Name City State
Haiti GHESKIO Port-au-Prince

Sponsors (6)

Lead Sponsor Collaborator
Brigham and Women's Hospital Analysis Group, Inc., Florida International University, Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic, University of California, Davis, Weill Medical College of Cornell University

Country where clinical trial is conducted

Haiti, 

Outcome

Type Measure Description Time frame Safety issue
Primary Retention in care with viral suppression Proportion of participants who are in care with HIV-1 RNA <200 copies/ml 48 weeks after HIV testing
Secondary Mortality All-cause mortality 48 weeks after HIV testing
Secondary Mean treatment cost per participant Mean treatment cost per participant 48 weeks after HIV testing
Secondary Viral suppression Proportion of participants with HIV-1 RNA <50 copies/ml and <1000 copies/ml 48 weeks after HIV testing
Secondary Adherence by medication possession ratio Proportion of participants with 48-week adherence to ART of at least 90% by pharmacy refill records 48 weeks after HIV testing
Secondary Adherence by 3-day self-report Proportion of participants with perfect (100%) adherence as measured by 3-day self-report at 48 weeks after HIV testing 48 weeks after HIV testing
Secondary Treatment failure Proportion of participants meeting WHO criteria for ART failure and proportion initiating second-line ART during the study period 48 weeks
Secondary TB testing characteristics Sensitivity, specificity, predictive values, and likelihood ratios of spot and early morning Xpert Ultra results and chest x-ray, as single and as combined tests, with liquid culture as gold standard These diagnostic tests will be conducted during the first week of study enrollment
Secondary Time in clinic Median time spent in clinic during first day and month of the study First study day and first study month
Secondary Coping with HIV diagnosis Scores on the COPE survey 2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
Secondary Connectedness to Treatment Setting Scores on the Connectedness to Treatment Setting Scale 2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
Secondary TB diagnosis after ART initiation Diagnosis of culture-positive TB after ART initiation (BACTEC MGIT 960, Becton Dickinson) 48-week study period
Secondary Incidence of immune reconstitution inflammatory syndrome (IRIS) Incidence of paradoxical or unmasking IRIS 48-week study period
Secondary Adverse events New Division of AIDS Grade 3 or Grade 4 signs, symptoms, or laboratory abnormalities that are at least a one-grade increase from baseline 48-week study period
Secondary Measure of hope and optimism Scores on the State Hope Scale 2 Weeks, 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
Secondary Patient satisfaction Scores on the HRSA Patient Satisfaction Survey 12 Weeks, 24 Weeks, and 48 Weeks after HIV Testing
Secondary Time to death Days to death 48-week study period
Secondary Last missed dose of medication Proportion of participants who report last missed dose of ART was at least 2 weeks ago 2 Weeks, 12 Weeks, 24 Weeks, 48 Weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05738681 - Efficacy of N-acetylcysteine to Prevent Anti-tuberculosis Drug-induced Liver Injury: A Randomized Controlled Trial Phase 2/Phase 3
Recruiting NCT05526885 - Tuberculosis Diagnostic Trial of CAD4TB Screening Alone Compared to CAD4TB Screening Combined With a CRP Triage Test, Both Followed by Confirmatory Xpert MTB/RIF Ultra in Communities of Lesotho and South Africa N/A
Completed NCT04369326 - Community Initiated Preventive Therapy for TB N/A
Recruiting NCT04568967 - TB-CAPT EXULTANT - HIV N/A
Completed NCT02337270 - Phase 1 Clinical Trial of the Safety and Immunogenicity of an Adenovirus-based TB Vaccine Administered by Aerosol Phase 1
Not yet recruiting NCT06253715 - Shortened Regimen for Drug-susceptible TB in Children Phase 3
Recruiting NCT04271397 - Immunological Biomarkers in Tuberculosis Management N/A
Withdrawn NCT03639038 - Tuberculosis Diagnosis by Flow Cytometry
Completed NCT03199313 - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid Phase 1
Recruiting NCT04975178 - Efficacy, Safety and Immunogenicity Evaluation of MTBVAC in Newborns in Sub-Saharan Africa Phase 3
Completed NCT04463680 - Rifampin and the Contraceptive Implant Phase 4
Completed NCT03973970 - Assessing the Ability of the T-SPOT®.TB Test (IQ)
Recruiting NCT04230395 - Alcohol Reduction Among People With TB and HIV in India N/A
Completed NCT04874948 - Absorption, Elimination and Safety of 14C-labeled Radioactive BTZ-043, a New Compound in TB Treatment Phase 1
Active, not recruiting NCT02906007 - Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis, Living With or Without HIV Phase 1/Phase 2
Not yet recruiting NCT05917210 - Peer-led Implementation of TB-HIV Education and Adherence Counseling in Uganda N/A
Not yet recruiting NCT06017843 - Impact Evaluation of Use of MATCH AI Predictive Modelling for Identification of Hotspots for TB Active Case Finding N/A
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Active, not recruiting NCT02715271 - Study of TB Lesions Obtained in Therapeutical Surgery
Completed NCT02781909 - Potential Efficacy and Safety of Using Adjunctive Ibuprofen for XDR-TB Tuberculosis Phase 2